Liposomal siRNA for ovarian cancer.
Discovery of RNA interference (RNAi) has been one of the most important findings in the last ten years. In recent years, small interfering RNA (siRNA)-mediated gene silencing is beginning to show substantial promise as a new treatment modality in preclinical studies because of its robust gene selective silencing. However, until recently, delivery of siRNA in vivo was a major impediment to its use as a therapeutic modality. We have used a neutral liposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), for highly efficient in vivo siRNA delivery. Using siRNA tagged with Alexa-555, incorporated in DOPC liposomes, we have demonstrated efficient intra-tumoral delivery following either intraperitoneal or intravenous injection. Furthermore, EphA2-targeted siRNA in DOPC liposomes showed significant target modulation and anti-tumor efficacy.
Mangala
Lingegowda S
LS
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Han
Hee Dong
HD
Lopez-Berestein
Gabriel
G
Sood
Anil K
AK
D000818:Animals; D002277:Carcinoma / Q000235:genetics / Q000628:therapy*; D005260:Female; D005456:Fluorescent Dyes / Q000737:chemistry; D020868:Gene Silencing; D015316:Genetic Therapy; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000235:genetics / Q000628:therapy*; D010713:Phosphatidylcholines / Q000737:chemistry*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000032:analysis / Q000627:therapeutic use*; D036104:Receptor, EphA2 / Q000235:genetics* / Q000378:metabolism
D005456:Fluorescent Dyes; D008081:Liposomes; D010713:Phosphatidylcholines; D034741:RNA, Small Interfering; D036104:Receptor, EphA2; C017251:1,2-oleoylphosphatidylcholine